Banyan BioInnovations Launches With $100M+ and ICON Partnership to Accelerate Clinical-Stage CRO Development

• Banyan BioInnovations has launched as an investment firm targeting clinical-stage drug assets, securing more than $100M in initial commitments and announcing a strategic collaboration and investment from ICON plc, a global CRO.

• The firm, powered by life sciences investment bank Locust Walk, will co-found NewCos around best or first-in-class clinical assets and provide centralized clinical development infrastructure — including operations, regulatory, and CMC — as a fee-for-service model.

Banyan BioInnovations has announced its launch as an investment firm that identifies best or first-in-class clinical-stage assets, forms NewCos around them, and provides centralized support to accelerate drug development. The Boston-based firm launched on May 5, 2026, with more than $100M in initial commitments from life science investors and a strategic collaboration and investment from ICON plc, positioning the CRO as a core execution partner across all Banyan-backed programs. 

Powered by Locust Walk, a global life sciences investment bank, Banyan Bio sources clinical-stage assets by leveraging Locust Walk’s offices in the life science hubs of Boston, San Francisco, Tokyo, Shanghai, and Beijing. The firm’s model is designed to bridge the gap between asset origination and clinical execution — providing each NewCo with disciplined capitalization from launch, a clear clinical objective, and access to a veteran centralized development team covering operations, regulatory affairs, and CMC on a fee-for-service basis. 

The ICON partnership reflects a deliberate move to embed CRO expertise at the earliest stages of drug development planning. Rather than engaging a CRO at the point of trial execution, Banyan Bio’s model integrates ICON from the due diligence phase, with the intent of improving trial design, accelerating execution, and aligning all parties — originators, investors, and the NewCo — around shared clinical milestones. ICON will provide feet-on-the-ground during clinical trials across Banyan Bio’s portfolio. 

Banyan Bio is launching with more than 50 team members at inception and is led by seasoned life sciences drug developers and dealmakers. Co-founder and CEO Geoff Meyerson previously co-founded and scaled Locust Walk over 17 years, closing more than 80 transactions. Co-founder and President Barbara White brings experience across large and small molecule development from biotech to big pharma, most recently serving as Chief Medical Officer and CEO of SFJ Pharmaceuticals. 

“Banyan Bio provides investors with a new model for funding the development of promising clinical-stage drug assets through clear value inflection points. Each Banyan Bio NewCo has a clear clinical objective to create asset value, disciplined and broad capitalization from launch, and access to world-class operational infrastructure.”

Geoff Meyerson, Co-founder and CEO, Banyan BioInnovations